NorthCoast Asset Management LLC bought a new position in shares of Celgene Co. (NASDAQ:CELG) during the third quarter, Holdings Channel reports. The fund bought 123,867 shares of the biopharmaceutical company’s stock, valued at approximately $18,062,000. Celgene comprises about 2.1% of NorthCoast Asset Management LLC’s investment portfolio, making the stock its 16th biggest position.

Other institutional investors and hedge funds have also bought and sold shares of the company. Janus Henderson Group PLC lifted its position in shares of Celgene by 4,290.5% in the 2nd quarter. Janus Henderson Group PLC now owns 8,408,961 shares of the biopharmaceutical company’s stock worth $1,092,071,000 after purchasing an additional 8,217,433 shares during the period. BlackRock Inc. lifted its position in shares of Celgene by 5.7% in the 2nd quarter. BlackRock Inc. now owns 56,725,342 shares of the biopharmaceutical company’s stock worth $7,366,919,000 after purchasing an additional 3,084,227 shares during the period. Oaktop Capital Management II L.P. acquired a new position in shares of Celgene in the 2nd quarter worth approximately $271,605,000. Arrowstreet Capital Limited Partnership lifted its position in shares of Celgene by 1,489.2% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 1,907,052 shares of the biopharmaceutical company’s stock worth $247,669,000 after purchasing an additional 1,787,052 shares during the period. Finally, Vanguard Group Inc. lifted its position in shares of Celgene by 3.1% in the 2nd quarter. Vanguard Group Inc. now owns 53,527,210 shares of the biopharmaceutical company’s stock worth $6,951,579,000 after purchasing an additional 1,610,056 shares during the period. 79.54% of the stock is currently owned by hedge funds and other institutional investors.

Celgene Co. (NASDAQ:CELG) opened at $102.65 on Monday. The company has a debt-to-equity ratio of 1.31, a quick ratio of 3.52 and a current ratio of 3.65. Celgene Co. has a 1-year low of $94.55 and a 1-year high of $147.17. The firm has a market cap of $80,818.09, a price-to-earnings ratio of 24.38, a price-to-earnings-growth ratio of 0.65 and a beta of 1.77.

Celgene (NASDAQ:CELG) last released its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.87 by $0.04. Celgene had a net margin of 27.36% and a return on equity of 63.80%. The firm had revenue of $3.29 billion for the quarter, compared to the consensus estimate of $3.42 billion. During the same quarter in the prior year, the company posted $1.58 earnings per share. The business’s revenue was up 10.2% on a year-over-year basis. equities analysts forecast that Celgene Co. will post 6.71 EPS for the current year.

A number of research analysts have recently issued reports on CELG shares. BMO Capital Markets boosted their price target on shares of Celgene from $148.00 to $155.00 and gave the stock an “outperform” rating in a research report on Friday, November 17th. Cantor Fitzgerald set a $112.00 price target on shares of Celgene and gave the stock a “hold” rating in a research report on Wednesday, January 17th. Oppenheimer restated a “buy” rating and issued a $170.00 price target on shares of Celgene in a research report on Friday, October 20th. Vetr upgraded shares of Celgene from a “buy” rating to a “strong-buy” rating and set a $144.39 price target on the stock in a research report on Monday, October 23rd. Finally, Cann reiterated a “buy” rating on shares of Celgene in a research report on Thursday, October 26th. Two investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the stock. Celgene has a consensus rating of “Buy” and an average target price of $129.98.

TRADEMARK VIOLATION WARNING: “NorthCoast Asset Management LLC Buys New Holdings in Celgene Co. (CELG)” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this story can be read at https://www.thecerbatgem.com/2018/01/22/northcoast-asset-management-llc-buys-new-holdings-in-celgene-co-celg.html.

About Celgene

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.